DIACEUTICS PLC

Declaration of Voting Results & Voting Rights Announcements • Jan 25, 2024

National Storage Mechanism | Additional information

RNS Number : 9506A

Diaceutics PLC

25 January 2024

Diaceutics PLC - Exercise of Warrant & Total Voting Rights

Belfast and London, 25 January 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to pharma and biotech companies, announces that it has received notification for the exercise of warrants over 177,915 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at an exercise price of £0.76 per share, providing the Company with proceeds of £135,215 ("Warrant Exercise").

Application has been made to the London Stock Exchange to admit the 177,915 new ordinary shares resulting from the Warrant Exercise to trading on AIM ("Admission"), which is expected to occur on at 8:00 am tomorrow 26 January 2024.  The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Warrant Exercise completes all outstanding warrants.

Following Admission, the total issued share capital of the Company will consist of 84,679,305 Ordinary Shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

Enquiries: 

Diaceutics PLC
Ryan Keeling, Chief Executive Officer	Tel: +44 (0)28 9040 6500
Nick Roberts, Chief Financial Officer	investorrelations@diaceutics.com
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Strategic Communications	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almastrategic.com
Matthew Young
Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRXELFLZFLFBBZ